Activation of Platelet-activating Factor (PAF) Receptor Stimulates Nitric Oxide (NO) Release Via Protein Kinase C-\(\alpha\) in HEC-1B Human Endometrial Epithelial Cell Line

Sharon Dearn\(^1\), Mabhub Rahman\(^1\), Aurélia Lewis\(^2\), Zahra Ahmed\(^1\), Margaret C. Eggo\(^2\), and Asif Ahmed\(^1\)

\(^1\)Department of Reproductive and Vascular Biology, Division of Reproductive and Child Health, Birmingham Women’s Hospital, University of Birmingham, Edgbaston, Birmingham, U.K. \(^2\)Division of Medicine, Queen Elizabeth Hospital, Edgbaston, Birmingham, U.K.

Accepted November 25, 1999.

Abstract

Background: Impairment of the fertility in the platelet-activating factor (PAF) receptor transgenic female mice suggests changes in PAF functions can influence uterine receptivity. We hypothesized that vasodilatory actions of PAF in the uterus was exerted by PAF-mediated nitric oxide (NO) release via activation of isoenzyme-specific protein kinase C (PKC).

Materials and methods: Inducible and endothelial NOS was shown by Reverse transcription polymerase chain reaction RT-PCR in cDNA synthesized from RNA extract of proliferative and secretory endometrium as well endometrial epithelial cell lines HEC-1B. The effect of WEB2170, \(N^\text{G}\) monomethyl-L-arginine (L-NMMA) and Ro31-8220 on PAF mediated NO release by HEC-1B cell was determined. PAF induced translocation of PKC\(\alpha\) in HEC-1B cell and its antagonist effect by Ro 31-8220 was studied by Western immunoblot analysis. PKC isoenzyme regulated by PAF was determined in HEC-1B cell lysate by immunoprecipitation.

Results: PAF-evoked a rapid and concentration-dependent biphasic increase in total NO in human HEC-1B endometrial epithelial cell line [as measured by a Sievers NOA 280A NO Chemiluminescent Analysers.] This increase in NO release was attenuated by the PAF receptor antagonist, WEB2170. Inhibition of NO synthesis by \(N^\text{G}\) monomethyl-L-arginine produced marked dose-dependent attenuation of PAF-mediated NO release, indicating nitric oxide synthase (NOS) activation. PAF-mediated NO release was also inhibited by the PKC-mediated NO release was also inhibited by the PKC inhibitor Ro 31-8220 and by the removal of extracellular calcium, suggesting a dependency on PKC and calcium, respectively. RT-PCR analysis showed expression of inducible NOS and endothelial NOS in human endometrium, myometrium and HEC-1B cells. Western immunoblot analysis showed PKC\(\alpha\), \(\beta\) and \(\iota\) were the principal isozymes present in the HEC-1B cell line and normal endometrium, suggesting that both HEC-1B cells and normal endometrium have similar PKC isozymes. PAF induced the translocation of both PKC\(\alpha\) and PKC\(\iota\) within the time frame of NO release. The translocation of PKC\(\alpha\), but not PKC\(\iota\), was susceptible to inhibition by Ro 31-8220 that also inhibited PAF-evoked NO release, suggesting that PKC\(\alpha\) is the principal isozyme involved in this process and that eNOS may be a substrate for PKC\(\alpha\). Kinase assays performed using immunoprecipitated PKC\(\alpha\) showed that PAF (1 nM) activated PKC\(\alpha\) that was inhibited by co-incubation with Ro31-8220 and Ca\(^{2+}\)-free medium.

Conclusions: This study demonstrates that PAF-stimulated NO release via PKC\(\alpha\) in epithelial cells might regulate endometrial functions such as implantation and menstruation.

Introduction

Platelet-activating factor (PAF) is a potent, inflammatory lipid mediator that increases vascular permeability and vasodilatation processes that accompany human implantation and men-
stricture (1,2). The potent vasodilatory and vascular permeability properties of PAF may relate to its ability to stimulate the release of agents such as nitric oxide (NO) (3), a labile intracellular messenger molecule which communicates blood vessel tone via activation of smooth muscle cytosolic guanylate cyclase (4). Furthermore, inhibition of endogenous NO synthesis can promote leakage of fluid and protein from capillaries (5), suggesting an important role for NO in regulating vascular permeability, a process closely associated with implantation (6). Formation of NO is achieved by the conversion of L-arginine to L-citrulline by the enzyme NO synthase (NOS) in the presence of molecular oxygen, NADPH and cofactors consisting of tetrahydrobiopterin, heme, flavin adenine dinucleotide and flavin mononucleotide (7). Three main isomers of NOS are neuronal (8), endothelial (9) and inducible NOS (10), displaying about 50% amino acid sequence homology. The two constitutively expressed NOS isozymes identified in endothelium and cerebellum are Ca$^{2+}$-dependent and calmodulin-dependent and they synthesize small amounts of NO upon activation. The third inducible NOS is Ca$^{2+}$-independent, although it binds calmodulin and is mainly seen in macrophages and neutrophils (11).

A recent study demonstrated the expression of endothelial NOS mRNA in the endometrial glandular epithelium, endometrial stroma and the myometrial blood vessels (12). Despite this and the suggestive importance of NO in implantation and menstruation (13,14), its production and regulation in human endometrium have not been described. Agonists that release endothelial NO share the ability to stimulate phospholipase C. PAF is known to stimulate phospholipase C from both normal endometrial tissue (15) and from endometrial epithelial cell line, HEC-1B cells (16). This activation generates two distinct second messengers: inositol (1,4,5)-trisphosphate and sn-1,2-diaclyglycerol, which activates protein kinase C (PKC). The endothelial NOS cDNA contains consensus sequences for phosphorylation by protein kinases including PKC and cyclic AMP-dependent protein kinase. NOS phosphorylation by PKC reduces NOS catalytic activity in the brain (17) and vascular endothelium (18), however in epithelial cells its actions are unknown.

PKC is not a single entity, but a family comprising at least 12 isozymes, which differ in their subcellular distribution, activation requirements and tissue expression (19,20). This suggests that each of the isozymes could have discrete functions in cell signaling. PKC isozymes activated following phospholipase activation can vary, offering a means to regulate cellular function via a common signaling pathway. PKC isozymes α, β and γ are Ca$^{2+}$-dependent; whereas, PKC isozymes δ, ε, ζ, η, θ are Ca$^{2+}$-independent. All of these isozymes, with the exception of μ, λ and ζ, are activated by phorbol ester, diacylglycerol and free fatty acids (20). Here we hypothesize that the vasodilatory effect of PAF may relate to its ability to stimulate the release of NO via PKC. The aim of this study was, therefore, to investigate the effect of PAF on the regulatory mechanisms involved in NO biosynthesis in HEC-1B cells, as this cell line was shown previously to possess functional PAF receptors and to retain many of the characteristics of endometrial epithelial cells (16).

Materials and Methods

Identification of the NOS Isozymes in the HEC-1B Cell Line

Normal endometrial tissue was obtained from women undergoing sterilization. Ethical approval was obtained from the South Birmingham Ethical Committee. Total RNA was extracted from proliferative and secretory endometrium as well as from monolayers of HEC-1B endometrial epithelial adenocarcinoma cells (American Type Culture Collection, Rockville, MD) by a single-step procedure based on the method of Chomczynski and Sacchi (21). Briefly, endometrial tissue was homogenized in RNAzol™ B (AMS Biotechnology (Europe) Ltd., Oxon, U.K.) while cell monolayers were lysed directly in the tissue culture flask and total RNA purified by acid-phenol extraction and ethanol precipitation. cDNA was synthesized from total RNA using the Superscript™ Preamplification System for first strand cDNA synthesis (GibcoBRL Life Technologies, Paisley, Scotland). Briefly, 10 μg of total RNA was primed with 0.5 μg/μl oligo(dT)$_{12–18}$ and reverse transcribed in a total volume of 20 μl of reaction mixture consisting of 10 mM of all four dNTP's, 25 mM MgCl$_2$, 0.1 M DTT and 200 units/μl of Superscript II RT in a buffer containing 200 mM tris-HCl (pH 8.4) and 500 mM KCl, according to the manufacturer’s instructions. For amplification by PCR, 2 μl of RT product was amplified with 2.5 units
Taq DNA polymerase and 10 μM of sense and antisense NOS primers in 50 μl of reaction mix containing 500 mM KCl, 200 mM tris-HCl and MgCl₂ [human inducible NOS (iNOS): 1.75 M; human constitutive endothelial NOS (eNOS): 1.5 M] for 35 cycles as follows: iNOS: 95°C, 30 sec; 55°C, 30 sec; 72°C, 60 sec; eNOS: 95°C, 30 sec; 60°C, 30 sec; 72°C, 60 sec Products were then analyzed by agarose gel electrophoresis. The sense primers for iNOS were 5'-GAATCTTGGAGCGAGTTGTGG-3' (nucleotide number: 2368-2350) and antisense were 5'-CCAGCTTCTTTAAGTGGTAG-3' (nucleotide number: 3286-3266). The sense primers eNOS were 5'-CCCCCCGAGCTCCCCGCTAAC-3' (nucleotide number: 135-155) and anti-sense were 5'-GCAGTCCCGGGCATCGAACAC-3' (nucleotide number: 629-649). The PCR products were subcloned and sequenced to confirm their identity.

**Preparation of Cell Lysates**

Cultured HEC-1B cells were maintained in 25 cm² flasks in Dulbecco’s modified Eagle’s medium (DMEM) containing 10% (v/v) fetal calf serum (FCS), 1% l-glutamine, 100 U/ml penicillin and 100 μg/ml streptomycin at 37°C, in 95% O₂ and 5% CO₂, in a humid atmosphere. For protein extraction, growth medium was removed and subconfluent (85%) monolayers washed with ice-cold PBS prior to the addition of 250 μl of lysis buffer. The buffer contained 50 mM Tris-HCl, pH 7.8, 1% Triton X-100, 0.1% SDS, 250 mM NaCl, 5 mM EDTA, 1 mM PMSF, 1 μg/ml aprotinin, leupeptin and pepstatin. Flasks were then shaken on an orbital shaker for 10 minutes at 4°C before transfer to prefrozen eppendorfs. Following centrifugation (13,000 rpm, 4°C, 10 min), the protein concentration of the supernatant was determined using the Bio-Rad protein assay (Bio-Rad Laboratories Ltd., Hertfordshire, U.K.) with BSA as standard.

**Western Immunoblot Analysis**

The non-radioactive ECL Western Blotting System was used to determine the PKC isozymes present in endometrial epithelial cell lysates. Briefly, 20 μg total protein was diluted to 20 μl with sample buffer (0.02 M tris-HCl, 0.002 M EDTA, 2% SDS, 10% 2-mercaptoethanol, 20% glycerol and 0.002% bromophenol blue) and electrophoresed in a 10% SDS-polyacrylamide minigel at 50 V for approximately 2 hr. After electrophoresis, proteins were transferred onto a nitrocellulose
membrane in a cooling system (10°C) for 3 hr at 50 V. The filter was blocked to reduce non-specific binding using tris-buffered-saline-tween (TBS-T) containing 5% skimmed milk and 0.1% BSA for 4 hr at room temperature. After washing in TBS-T (3 × 20 minutes), the membrane was blocked to reduce non-specific binding using tris-buffered-saline-tween (TBS-T) containing 5% skimmed milk and 0.1% BSA for 4 hr at room temperature. After washing in TBS-T (3 × 20 minutes), the membrane was incubated overnight at 4°C with affinity purified antibodies specific to various members of the PKC family (PKCs α, β1 and β2, δ, ε, η, τ and ζ; Binding site, Birmingham, U.K.) and diluted 1:500. The amino acid sequences against which these antibodies were raised are specific for each isozyme. The amino acid sequences against which the three key antibodies used in this study are given below:

- **anti-PKC-iota antibody**: PSSHESLDQV-GEEKEAMNTRESGK (between amino acids 212 and 235).
- **anti-PKC-zeta antibody**: EETDGIAYISS-SRKHSIKDDSED (between amino acids 199 and 222).
- **anti-PKC-alpha antibody**: PSEDRKQP-SNNLDRV (between amino acids 320-334).

Filters were washed and incubated with the secondary peroxidase-labeled anti-sheep antibody diluted 1:10,000 for 2 hr at room temperature. After a final wash in TBS-T, filters were incubated for 1 min at room temperature in detection reagent, immediately wrapped in saran wrap and exposed to X-ray film. A single band of the molecular weight of the full-length isozyme was found for PKCs α, β11, ε and τ. For other PKC isozymes, the staining of the full-length PKC isozymes was weak and indistinguishable from nonspecific staining.

**Cell Treatment and Subcellular Fractionation**

HEC-1B cells were maintained in 25 cm² flasks as previously described. Before agonist stimulation, growth medium was removed and near confluent monolayers serum-starved for 24 hr. Stimulation was initiated by the addition of 1 nM PAF in DMEM without fetal calf serum and cultures treated for the times indicated. After removal of the medium, cells were rinsed with ice-cold PBS and then scraped into 250 μl of sonication buffer (0.25 M sucrose, 10 mM DTT, 2 mM μg/ml leupeptin). Cells were then sonicated (Soniprobe, setting 5) for 3 × 10 sec and the soluble and particulate fractions separated by centrifugation at 100,000 × g for 30 min (Beckman TLA 120.1 fixed angle rotor, Beckman Instruments UK Ltd., Buckinghamshire, U.K.). The supernatants were collected, and the membrane pellets were suspended in 150 μl of sonication buffer, sonicated for 3 × 10 sec, incubated for 30 min, and then centrifuged at 100,000 × g for 30 min. The resulting supernatants were designated membrane fractions. The protein concentrations of cytosolic and membrane fractions were determined and Western immunoblot analysis performed as previously described.

**Protein Kinase Cα Assay**

Cells were incubated for 24 hr in medium without serum. Ro31-8220 was added 30 min prior PAF (1 to 10nM) and incubation was continued for another 60 min. Medium was removed and the method of Monks et al. (23) for preparing cell lysates was followed. Cell lysates (100 μl) were incubated overnight at 4°C with 0.2 μg immunoglobulin G (IgG) to PKCα. Immunoprecipitates were incubated with Protein G (formalin fixed; volume added according to the manufacturer instructions) for 2 hr on ice and washed 3 × with PKC kinase buffer without β-glycerophosphate. The kinase reaction was performed as described, but 3.5 μg histone H1 was used and [γ³³P]ATP (2 μCi/assay) was substituted for [γ³²P]ATP. The reaction was stopped by adding reducing sample buffer (2×) and samples were boiled for 10 min. Samples were run on a 10% SDS-PAGE gel and proteins were transferred to a PVDF membrane (Amersham Pharmacia, Buckinghamshire, U.K.). ³³P-labeled proteins were determined by autoradiography.

**Statistical Analysis**

All data are expressed as mean ± S.E.M. Statistical analysis was performed using Student’s dependent (unpaired) and dependent (paired) t-test. These tests were performed on log normalized data.

**Results**

Amplification of cDNA from HEC-1B cells by RT-PCR using primers directed against the inducible and the endothelial NOS isozymes, produced a single band for each of the predicted size (Fig. 1A and B). Sequencing con-
firmed these to be inducible and endothelial NOS, respectively.

Consistent with activation of a constitutive NOS, NO formation increased rapidly in response to 1 nM PAF, exceeding basal release by 5.6% ± 0.65% within 30 sec, the earliest time point measured \( p < 0.01, n = 4 \); Fig. 2) and reaching a maximum within 10 min of stimulation. Thereafter, total NO levels reached a plateau, but remained elevated. Addition of PAF receptor antagonist WEB2170 after 15 min of PAF stimulation inhibited PAF-evoked NO release in a time-dependent manner (Fig. 2) indicating that PAF-mediated NO release appears to be sustained over the time period studied. The increase in total NO evoked by PAF within the concentration range tested (1 pM to 1 μM) was completely blocked by addition of WEB 2170 (10 μM) at the time of stimulation in all instances, except that which evoked maximal NO release (Fig. 3) indicating a PAR receptor–mediated response. Moreover, NO release appeared to be biphasic and that may reflect the involvement of two different receptor subtypes (Fig. 3). PAF receptor activation involves NOS activation, as indicated by the marked dose-dependent attenuation of PAF-evoked NO release by the NOS inhibitor Nω-monomethyl-L-arginine (L-NMMA; 1 nM to 1 mM), with half-maximal inhibition (IC₅₀) at approximately 1 μM (Fig. 4A).

The role of external Ca²⁺ and PKC were determined by conducting experiments in the presence of both low Ca²⁺ buffer and Ro 31-8220, a selective PKC inhibitor to identify the regulatory mechanisms involved in PAF-stimulated NO release. In the experiment shown in Figure 4B, the PAF-evoked NO release is PKC–dependent as Ro 31-8220 attenuated this response. Pretreatment of HEC-1B cells with 1 μM Ro 31-8220 inhibited PAF-mediated NO release by 80% (Fig. 4B). In the presence of ex-
ternal Ca\(^{2+}\), 1 nM PAF evoked a significant increase in total NO release. In contrast, when stimulations were conducted in the presence of low Ca\(^{2+}\) buffer (150 nM), PAF-mediated NO release was significantly inhibited. Compared with control incubation performed in the same low Ca\(^{2+}\) buffer, PAF stimulated NO was just 19.3% \pm 1.68% above control, suggesting a dependency on extracellular Ca\(^{2+}\) (\(p < 0.0001, n = 9\)).

To identify the PKC isozymes involved in PAF-stimulated NO release, the PKC isozyme profile of the HEC-1B cell line was determined and the isozymes translocated in response to PAF stimulation within the time frame of NO production were identified. Western immunoblot analysis of whole cell extracts established that the HEC-1B cell line contained all but one of the eight PKC isozymes tested. PKCa, \(\beta I\), \(\epsilon\) and \(\iota\) were identified as the major isozymes present (data not shown). PKC\(\beta I\), \(\delta\) and \(\eta\) were weakly positive. In contrast, PKC\(\zeta\) was not present in detectable amounts.

All of the PKC isozymes were located predominantly in the cytosolic fraction of unstimulated cells, as shown for PKCa and PKCi in Fig. 6 and Fig. 7, respectively. Treatment of cells with 1 nM PAF induced a rapid translocation of PKCa, as detected by Western immunoblot analysis. Analysis of membrane fractions with a PKCa-specific antibody showed that this isozyme associated with the membrane 1 min after PAF addition where it remained, to approximately the same extent, following 2, 5, 10 and 20 min of stimulation (Fig. 5A). This translocation was completely abolished by pre-treatment and stimulation in the presence of the PKC inhibitor, Ro 31-8220 (Fig. 5B). PKCi was similarly located predominantly in the cytosol of resting confluent HEC-1B cells (Fig. 6). Analysis of membrane fractions with a PKCi-specific antibody showed that this isozyme associated with the membrane 30 sec after PAF addition, with levels increasing progressively over the next 10 min of stimulation, only to return to the levels observed within 1 min of stimulation by 20 min (Fig. 6A). In contrast to the translocation observed with PKCa,

![Fig. 3. Dose-dependent release of nitric oxide (NO) from human HEC-1B cells.](image-url)

HEC-1B cells were plated at a density of 300,000 cells/ml in 24 well plates and grown to 80% confluency in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal calf serum. Following serum starvation, near confluent monolayers were stimulated for 30 min with an increasing concentration of platelet-activating factor (PAF; solid circle) or an increasing concentration of platelet-activating factor in the presence of 10 \(\mu\)M WEB2170 (open circle). The media was removed and NO levels determined using a Sievers NOA 270B chemiluminescent analyser. The results are expressed as means \pm S.E.M. of a typical experiment (triplicate determinations per experiment; 3 similar experiments). Basal NO release was 1482 pmol/well and has not been subtracted from the data.
Fig. 4. Antagonistic effect of N\(_{G}\)-monomethyl-L-arginine (L-NMMA), low \(\text{Ca}^{2+}\) and Ro31-8220 on PAF mediated NO release by HEC-1B cell due to activation of NOS and PKC. (A) Effect of inhibition of NO synthesis by L-NMMA on PAF-mediated NO release. HEC-1B cells were stimulated for 30 min with 1 nM platelet-activating factor in the presence of increasing concentrations of N\(_{G}\)-monomethyl-L-arginine. The media was removed and NO levels determined using a Sievers NOA 270B chemiluminescent analyser. The results are expressed as means ± S.E.M. of a typical experiment (triplicate determinations per experiment; 3 similar experiments). Basal NO release was 2150 pmol/well and PAF-mediated NO release in the absence of L-NMMA was 2995 pmol/well. These values have not subtracted from the data. (B) Effect of inhibition of protein kinase C and low external \(\text{Ca}^{2+}\) and on PAF-mediated NO release from HEC-1B cells. Following serum starvation, confluent monolayers were washed with sterile PBS and pre-treated at 37°C with low \(\text{Ca}^{2+}\) buffer (150 nM external \(\text{Ca}^{2+}\)) or with Ro 31-8220 at 1 \(\mu\)M 30 min. Cells were then stimulated with 1 nM PAF in standard media, in the presence of low \(\text{Ca}^{2+}\), in the presence of 1 \(\mu\)M Ro 31-8220 for 30 min. The results are expressed as means ± SEM of a representative experiment (\(n = 9\); 2 similar experiments).
however, translocation of PKCα was unaffected by pre-treatment and stimulation in the presence of the PKC inhibitor, Ro 31-8220 (Fig. 6B). No change in the cellular localization of all other PKC isozymes tested was observed in response to PAF stimulation.

Activation of PKCα in response to PAF was determined in kinase assays shown in figure 7A. PAF (1 nM) produced pronounced activation of PKCα after 1 hr incubation. This effect was diminished at 10 nM PAF. This pattern mimics the high activity seen with 1 nM PAF in NO assays and the decrease seen at 10 nM PAF (Fig. 3). The PKC inhibitor Ro31-8220 completely blocked activation by 1 nM PAF. Studies in Ca2+-free Hank’s balanced salt solution showed that PAF (1 nM) was unable to activate PKCα (Fig. 7B). Similarly PAF did not activate PKCα when cells were cultured in medium containing 1 mM EGTA. In fact, in both Ca2+-free salt solution and EGTA-supplemented medium, PKCα kinase activity was higher in the control incubations than the PAF-stimulated samples.

Discussion

This is the first study to conclusively demonstrate that activation of PAF receptor stimulates the release of NO from a human endometrial epithelial cell line and that this response is dependent on PKCα activation. The release of NO was rapid and Ca2+-dependent, consistent with activation of a constitutive isoform of NOS (24). The presence of mRNA encoding constitutive endothelial NOS was demonstrated by RT-PCR and is in agreement with
the identification of this isoform in the human uterus (12). The HEC-1B cells were also shown to express mRNA for inducible NOS, as is the case with human bronchial epithelial cells (25). The observed PAF-evoked NOS activation is, however, unlikely to be due to inducible NOS induction, not only because of the rapidity and magnitude of the response, but also with respect to its Ca^{2+}-dependence. Moreover, attenuation of this effect by the PAF receptor antagonist, observed following addition of 10 µM WEB2170 after 15 min stimulation of cells with 1 nM PAF, suggests that PAF-evoked NO release is sustained rather than transient, despite peaking within 10 min of stimulation and then plateauing. This finding is in contrast to that observed with other Ca^{2+}-mobilizing agonists, such as Bradykinin, where the response was transient (26,27).

PAF-mediated NO release appears to be biphasic, 1 nM-PAF evokes maximal NO release while a further significant release of NO, of smaller magnitude, is evoked by 1 µM PAF, a result which may reflect the involvement of both high and low affinity receptors in NO generation. The presence of a heterogeneous population of PAF receptors in HEC-1B cells is consistent with the identification of two distinct PAF isoreceptors in a second human adenocarcinoma cell line derived from uterine epithelium, HEC-1A (28). PAF receptor binding studies in a number of tissues have shown the presence of high and low affinity receptor sites (28,29). Autoradiography studies have indicated binding sites for PAF in the rabbit endometrium (30) and RT-PCR revealed the expression of PAF receptor mRNA in the HEC-1B cell line (16) and in situ hybridization demon-
strated the localization of PAF receptor mRNA in endometrial glands (2,31). Our studies clearly show a biphasic response with PAF on NO release, thereby, suggesting the existence of receptor subtypes.

In HEC-1B cells, PAF activates phospholipase C to yield sn-1,2 diacylglycerol and inositol (1,4,5) trisphosphate (16). Inositol (1,4,5) trisphosphate induces an elevation of intracellular Ca^{2+}, [Ca^{2+}]_{i}, required for Ca^{2+}-dependent processes (31). Elevated [Ca^{2+}]_{i} increases the activity of phospholipases. PAF also evokes a concentration-dependent rise in [Ca^{2+}]_{i} in HEC-1B cells, an effect which is inhibited by WEB 2086, suggesting that it is mediated by a specific PAF receptor (16). The observation that PAF-mediated NO release is attenuated by the removal of Ca^{2+} from the external environment suggests dependency on extracellular Ca^{2+}. However, since the response was not completely abolished in its absence, this suggests dependency not only on extracellular Ca^{2+}, but also that released from intracellular stores.

Protein kinase C inhibitor Ro 31-8220–attenuated NO production in response to PAF suggests that PKC may modulate the release of NO from HEC-1B cells. Ro 31-8220 has been shown to inhibit members of the conventional PKC family (PKCa, β and γ), which are Ca^{2+}- and phospholipid-dependent (33). Ro 31-8220 appears to have selectivity for PKCa over PKCβ, PKCγ and PKCe (33), the latter a representative of the Ca^{2+}-independent PKC family. The inhibitory effect of Ro 31-8220 and the Ca^{2+}-dependence suggests a role for a member of the conventional PKC family in the regulation of PAF-mediated NO release. The absence of isozyme-specific PKC inhibitors, however, makes it difficult to determine the involvement of specific isozymes. Consideration must also be given not only to the possible selectivity of the inhibitors for certain PKC isozymes, but also to the potential non-kinase effects of such agents at high concentrations. We, therefore, performed functional analysis of PKC activity, as well as determined the expression of PKC isozymes in HEC-1B cells.

Western immunoblot analysis revealed that the HEC-1B cell line expresses isozymes representative of all three PKC subfamilies. Major isozymes were identified as PKCa, βII, ε and τ, the two former isozymes representing members of the conventional or calcium-dependent PKC family, and the two latter members of the novel or calcium-independent and atypical PKC families, respectively. PKCβI, δ and η, the former a member of the conventional PKC family, and the latter two members of the novel or calcium-independent PKC family were also weakly positive on immunoblots. PKCζ, a member of the atypical PKC family, was not present in detectable amounts. The isozyme profile in HEC-1B cell line was similar to that observed in normal human endometrium (2). Investigations into the isozymes translocated in response to PAF stimulation, within the time frame of NO production, revealed that both PKCa and PKCe are translocated from the cytosol to the membrane upon PAF stimula-
tion. The translocation of PKCα from the cytosol to the membrane in response to PAF is consistent with that observed in human endothelial cells (34). Liu et al. (35), using Chinese hamster ovary cells stably expressing wild type guinea pig PAF receptor, also found translocation of PKCα to the membrane following PAF stimulation. PKCε is unlikely to be involved since translocation of the ε isozyme upon PAF stimulation was unaffected by the PKC inhibitor, Ro 31-8220. Although there are no data showing that PKCε is sensitive to Ro31-8220, indicating that the involvement of PKCε in PAF-mediated NO release can not be ruled out, it is clear from the almost complete inhibition of PAF-evoked NO release by Ro 31-8220 that this effect is mediated by PKCα. Kinase assays showed that PKCα activity was stimulated following 1 hr challenge with 1 nM PAF and that this activation was inhibited by Ro 31-8220 and was Ca2+ sensitive. Furthermore, as for NO synthesis, higher concentrations of PAF (10 nM) resulted in the return of PKCα activity to control levels. The principal PKC isozyme implicated in PAF-mediated NO release is PKCα in HEC-1B cells.

A previous study showed that PKC activation and eNOS phosphorylation resulted in inhibition of NO production from bovine aortic endothelial cells (18). In contrast, our study demonstrates that PKC activation leads to NO production in cells of epithelial origin. Similarly, a recent study by Garcia-Cardena et al. (36) showed that heat shock protein 90 (Hsp90) rapidly associates with eNOS on growth factor stimulation, resulting in NO production. Hsp90 is postulated to act as a scaffold to allow interaction of eNOS with other regulatory proteins. We have not determined whether eNOS is a substrate of PKCα in HEC-1B cells or whether Hsp90 forms a complex, but our data illustrate the diversity in response to PAF in different cell types.

PAF-induced vasodilatation in the rabbit afferent arteriole is highly dependent upon intact endothelium-derived NO synthesis (3). Recent reports suggest that the endothelium-dependent vasodilator effects of PAF are primarily mediated by endothelium-derived NO (37) and that NO contributes to the PAF-induced hypo-responsiveness to noradrenaline with no major role for cyclo-oxygenase products in this process (38). The ability of the endometrium to respond to PAF appears to be a feature of the preparation of this tissue for implantation in women (15,31). The restricted PAF receptor expression pattern obtained in establishing transgenic mice suggests that the ubiquitous hyper-expression of the PAF receptor is embryonically lethal to mice (39). Furthermore, the role of PAF receptor in reproduction is indicated by the impairment of fertility in the transgenic female, which is affected by the transgene to a greater extent then the transgenic male (39). Moreover, it was previously demonstrated that failure in the regulation of PAF metabolism led to premature delivery and infertility (40,41). It is also interesting to note that mice deficient of the cytosolic phospholipase A2, the enzyme involved in the synthesis of PAF, prostaglandins and leukotrienes, displayed a reduction in fertility (42). However, PAF-receptor deficiency did not cause abnormalities in mice fertility (43), suggesting that other mechanisms of compensation are able to overcome the lack of this receptor. Alternatively, although there is no evidence for structural isoforms of the canonical PAF receptor from mRNA analysis, pharmacological studies in a variety of cell types suggest the existence of different PAF receptor subtypes (44). This study demonstrates that vasodilatation actions of PAF are likely to be due to NO release via PKCα and proposes that NO might both augment the vasodilatory effects of PAF in the preparation of a receptive endometrium for implantation and play a role in the regulation of menstruation.

Acknowledgment

This work was supported by grants from the Medical Research (Grant no. G9415051 and G9602173) British Heart Foundation (Grant no PG96144) to AA. The authors also appreciate Dr. C. H. Weber, Boehringer Ingelheim Limited (Bracknell, Berkshire U.K.) for the generous gift of WEB 2170.

References

1. Ahmed A, Smith SK. (1992) The endometrium: prostaglandins and intracellular signalling at implantation. Balliere’s Clinical Obstet. Gynaecol. 6: 731–754.
2. Ahmed A, Dearn S. (1997) The role of platelet-activating factor and its receptor in endometrial receptivity. In: Nigam S (ed.) Platelet-activating Factor and Related Lipid Mediators in Health
13. Juncos L.A, Ren Y, Arima S, Ito S. (1993) Vasodilator and constrictor actions of platelet-activating factor in the isolated microperfused afferent arteriole of the rabbit kidney. Role of endothelium-derived relaxing factor/NO and cyclooxygenase products. *J. Clin. Invest.* 91: 1374–1379.

14. Palmer RMJ, Ferrige AG, Moncada S. (1989) Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. *Nature* 327: 524–526.

15. Filep JG, Foldes-Filep E, Sirois P. (1993) Nitric oxide modulates vascular permeability in the rat coronary circulation. *Br. J. Pharmacol.* 108: 323–326.

16. McRae AC, Heap RB. (1988) Uterine vascular permeability blood flow and extracellular fluid space during implantation in rats. *J. Reprod. Fertil.* 82: 617–625.

17. Lowenstein CJ, Snyder SH. (1992) Nitric oxide, a novel biological messenger. *Cell* 70: 705–707.

18. Breit DS, Hwang PM, Glatt CE, Lowenstein C, Reed RR, Snyder SH. (1991) Cloned and expressed nitric oxide synthase structurally resembles cytochrome P-450 reductase. *Nature* 351: 714–718.

19. Marsden PA, Schappert KT, Chen HS, Flowers, M, Sundell CL, Wilcox JN, Lamas S. et al. (1992) Molecular cloning and characterization of the constitutive bovine aortic endothelial cell nitric oxide synthase. *J. Clin. Invest.* 90: 2092–2096.

20. Xie QW, Cho HJ, Calaycay J, Mumford RA, Swiderek KM, Lee TD, Ding A, et al. (1992) Cloning and characterization of nitric oxide synthase from mouse macrophages. *Science* 256: 225–228.

21. Knowles RG, Moncada S. (1992) Nitric oxide as a signal in blood vessels. *Trend. Biochem. Sci.* 17: 399–402.

22. Telfer JF, Lyall F, Norman JE, Cameron IT. (1995) Identification of nitric oxide synthase in human uterus. *Hum. Reprod.* 10: 19–23.

23. Chaudhuri G., Nathan L. (1992) Nitric oxide and cyclooxygenase products. *J. Clin. Invest.* 91: 1374–1379.

24. Ahmed A, Smith SK. (1992) Platelet activating factor stimulates phospholipase C activity in human endometrium. *J. Cell Physiol.* 152: 207–214.

25. Ahmed A, Sage SO, Plevin R, Shoalbi M.A, Sharkey AM, Smith SK. (1994) Functional platelet-activating factor receptors linked to inositol lipid hydrolysis, calcium mobilization and tyrosine kinase activity in the human endometrial HEC-1B cell line. *J. Reprod. Fertil.* 101: 459–466.

26. Breit DS, Ferris CD, Snyder SH. (1992) Nitric oxide synthase regulatory sites. *J. Biol. Chem.* 267: 10976–10981.

27. Hirata K, Kuroda R, Sakoda T, Katayama M, Inoue N, Suematsu M, Kawashima S, et al. (1995) Inhibition of endothelial nitric oxide synthase activity by protein kinase C. *Hypertension* 25: 180–185.

28. Ahmed A, Sage SO, Plevin R, Shoalbi M.A, Sharkey AM, Smith SK. (1994) Functional platelet-activating factor receptors linked to inositol lipid hydrolysis, calcium mobilization and tyrosine kinase activity in the human endometrial HEC-1B cell line. *J. Reprod. Fertil.* 101: 459–466.

29. Breit DS, Ferris CD, Snyder SH. (1992) Nitric oxide synthase regulatory sites. *J. Biol. Chem.* 267: 10976–10981.

30. Hirata K, Kuroda R, Sakoda T, Katayama M, Inoue N, Suematsu M, Kawashima S, et al. (1995) Inhibition of endothelial nitric oxide synthase activity by protein kinase C. *Hypertension* 25: 180–185.
31. Ahmed A, Dearn S, Sangha R, Li XF, Shams M, Rola-Pleszczynski M, Jiang J. (1998) Localization, quantification and activation of platelet-activating factor receptor in human endometrium during the menstrual cycle: PAF stimulates NO, VEGF and FAK. **FASEB J.** 12: 671–683.

32. Barzaghi GH, Sarau M, Mong S. (1989) Platelet-activating factor-induced phosphoinositide metabolism in differentiated U-937 cells in culture. **J. Pharmacol. Exp. Therap.** 248: 559–566.

33. Wilkinson SE, Parker PJ, Nixon JS. (1993) Isoenzyme specificity of bisindolylmaleimides, selective inhibitors of protein kinase C. **Biochem. J.** 294: 335–337.

34. Bussolino F, Silvagno F, Garbarino G, Costamagna C, Sanavio F, Arese M, Soldi R, et al. (1994) Human endothelial cells are targets for platelet-activating factor (PAF): activation of alpha and beta protein kinase C isoforms in endothelial cells. **J. Biol. Chem.** 269: 2877–2886.

35. Lui B, Nakashima S, Takano T, Shimizu T, Nozawa Y. (1995) Implication of protein kinase C alpha in phospholipase activation in Chinese hamster ovary cells expressing PAF receptor. **Biochem. Biophys. Res. Commun.** 214: 418–423.

36. Garcia-Cardena G, Fan R, Shah V, Sorrentino R, Cirino G, Papapetropoulos A, Sessa WC. (1998) Dynamic activation of endothelial nitric oxide synthase by Hsp 90. **Nature** 392: 821–824.

37. Kamata K, Numazawa T, Kasuya Y. (1996) Characteristics of vasodilatation induced by acetylcholine and platelet-activating factor in the rat mesenteric arterial bed. **Eur. J. Pharmacol.** 298: 129–36.

38. Shiga T, Yoshikawa D. (1995) Platelet-activating factor-induced loss of vascular responsiveness to noradrenaline in pithed rats: involvement of nitric oxide. **Eur. J. Pharmacol.** 282: 151–156.

39. Ishii S, Nagase T, Tashiro F, Ikuta K, Sato S, Waga I, Kume, K, et al. (1997) Bronchial hyper-reactivity, increased endotoxin lethality and melanocytic tumorigenesis in transgenic mice overexpressing platelet-activating factor receptor. **EMBO J.** 16: 133–142.

40. Narahara H, Tanaka Y, Kawano Y, Gholbzouri K, Miyakawa I, Johnston JM. (1995) Platelet-activating factor-acetylhydrolase activity in follicular fluid of patients undergoing in vitro fertilization and embryo transfer. **Fertil. Steril.** 64: 1172–1176.

41. Toyoshima K, Narahara H, Furukawa M, Frenkel RA, Johnston JM. (1995) Platelet-activating factor. Role in fetal lung development and relationship to normal and premature labor. **Clin. Perinatol.** 22: 263–280.

42. Bonventre JV, Huang Z, Taheri MR, O'Leary E, Li E, Moskowitz MA, Sapirstein A. (1997) Reduced fertility and postischaemic brain injury in mice deficient in cytosolic phospholipase A2. **Nature** 390: 622–625.

43. Ishii S, Kuwaki T, Nagase T, Maki K, Tashiro F, Sunaga S, Cao W-H, et al. (1998) Impaired anaphylactic responses with intact sensitivity to endotoxin in mice lacking a platelet-activating factor receptor. **J. Exp. Med.** 187: 1779–1788.

44. Chen J, Giri SN. (1997) Differences in platelet-activating factor receptor mediated Ca++ response between hamster and guinea pig alveolar macrophages. **J. Pharmacol. Exp. Ther.** 281: 1047–1058.